Clinical Trial Update: A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intravenous administration of three broadly neutralizing monoclonal antibodies (VRC07-523LS, PGT121.414.LS, and PGDM1400LS) fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• PGDM1400LS
• PGT121.414.LS
• VRC07-523LS

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV | Phase 2 | Status: RECRUITING